ALLERGIC REACTION UPON INTRAVITREAL ADMINISTRATION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS.
Retin Cases Brief Rep
; 13(3): 287-289, 2019.
Article
em En
| MEDLINE
| ID: mdl-28301410
ABSTRACT
PURPOSE:
To describe the patient's allergic response to anti-vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization.METHODS:
Clinical case report.RESULTS:
Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept.CONCLUSION:
Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Inibidores da Angiogênese
/
Hipersensibilidade a Drogas
/
Bevacizumab
/
Ranibizumab
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Retin Cases Brief Rep
Ano de publicação:
2019
Tipo de documento:
Article
País de publicação:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA